What’s New in CNS Medicine? Key Clinical Developments Across CNS:
The field of central nervous system (CNS) medicine continues to evolve rapidly, with new clinical trials, therapeutic approaches, and technological innovations emerging across multiple neurological conditions. From advances in mechanical thrombectomy in acute ischemic stroke to promising developments in gene and cell therapies for Parkinson’s disease and epilepsy, recent research highlights the breadth of innovation currently shaping neurology.
Stroke: Intra-arterial thrombolytics following thrombectomy – insights from the CHOICE-2 trial
Mechanical thrombectomy has become a cornerstone of treatment for acute ischemic stroke caused by large vessel occlusion. However, researchers continue to explore strategies to improve outcomes following successful clot retrieval. The CHOICE-2 trial investigated whether administering intra-arterial thrombolytic therapy after thrombectomy could enhance reperfusion and improve functional outcomes.
Continue reading here:
https://www.tctmd.com/news/choice-2-bolsters-intra-arterial-lytics-after-stroke-thrombectomy
Stroke: New thrombectomy devices under investigation – the GRASSROOT trial
Device innovation continues to drive progress in endovascular stroke treatment. The GRASSROOT trial evaluated the Supernova stent retriever, a next-generation thrombectomy device designed to improve clot retrieval efficiency in acute ischemic stroke.
Continue reading here:
https://jnis.bmj.com/content/early/2025/12/09/jnis-2025-024470
Stroke: Expanding the thrombectomy treatment window beyond 24 hours
Another key area of research in stroke medicine is the potential expansion of the time window for mechanical thrombectomy. New studies are exploring whether carefully selected patients may still benefit from treatment beyond traditional time limits.
Continue reading here:
https://pmc.ncbi.nlm.nih.gov/articles/PMC12028478/
Parkinson’s disease: Stem-cell therapies entering late-stage clinical trials
Regenerative medicine approaches are gaining increasing attention in Parkinson’s disease. One strategy involves transplanting dopamine-producing cells into the brain to restore neural pathways affected by the condition.
Continue reading here:
Parkinson’s disease: iPSC-derived cell therapies receive regulatory momentum
Another promising area of Parkinson’s research involves induced pluripotent stem cell (iPSC)-derived dopaminergic neurons. These therapies aim to replace cells lost during disease progression and restore dopamine signalling.
Continue reading here:
Parkinson’s disease: Emerging therapies including tavapadon and bemdaneprocel
Several novel pharmacological treatments are under development for Parkinson’s disease, including tavapadon and bemdaneprocel. These approaches reflect the increasingly diverse therapeutic pipeline in Parkinson’s research.
Continue reading here:
https://www.apdaparkinson.org/article/new-parkinsons-therapies-tavapadon-bemdaneprocel/
Epilepsy: Genetic therapy approaches for Dravet syndrome
Precision medicine approaches are beginning to transform treatment strategies for rare epilepsies. Zorevunersen targets genetic mechanisms underlying Dravet syndrome and early results suggest significant seizure reductions.
Continue reading here:
Epilepsy: Gene therapy development for STXBP1 encephalopathyGene therapy research is also progressing for other rare epileptic conditions. CAP-002, targeting STXBP1 developmental and epileptic encephalopathy, has received Fast Track designation from the FDA.
Continue reading here:
Keeping up with CNS research
Useful resources for tracking CNS research developments:
Clinical trials registry: https://clinicaltrials.gov
Neurology research news: https://www.neurologylive.com
European Stroke Organisation updates: https://eso-stroke.org
American Heart Association journals: https://www.ahajournals.org